Metronidazol Basi

Metronidazole, the active ingredient in Metronidazol Basi, is a nitroimidazole presented as an intravenous solution for parenteral use. It treats a range of anaerobic bacterial and protozoal infections in adult patients. GNH USA supplies Metronidazol Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metronidazol Basi, a nitroimidazole, is employed against infections caused by anaerobic bacteria and certain protozoa. - Anaerobic bacterial infections: effective in reducing bacterial load in intra‑abdominal, pelvic and soft‑tissue infections. - Bacterial vaginosis: restores normal vaginal flora by eliminating pathogenic anaerobes. - Trichomoniasis: eradicates Trichomonas vaginalis, relieving symptoms and preventing transmission. - Amoebiasis: treats intestinal and extra‑intestinal infections caused by Entamoeba histolytica. - Clostridioides difficile infection: suppresses toxin‑producing C. difficile strains in moderate to severe cases.

Metronidazol Basi may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient metallic sensation in the mouth. - Headache: occasional dull or throbbing pain. - Diarrhoea: loose stools that may be watery. - Abdominal pain: cramping or discomfort in the stomach area. - Dizziness: light‑headed feeling, especially on standing.

Serious or Rare Side Effects: - Seizures: rare neurologic events requiring immediate care. - Peripheral neuropathy: tingling or numbness in extremities. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin and mucous membrane disorder. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Neutropenia: marked reduction in white blood cells.

Before using Metronidazol Basi, consider the following safety measures. - Renal function: adjust or monitor in patients with severe renal impairment. - Hepatic function: use cautiously in individuals with liver disease. - Alcohol consumption: avoid alcohol during therapy and for at least 48 hours after the last dose to prevent a disulfiram‑like reaction. - Pregnancy: safety not established; weigh potential benefits against risks. - Concomitant medications: review for possible interactions, especially anticoagulants and neurotoxic agents. - Store at below 25°C: keep in the original container, protect from moisture and light.

Metronidazol Basi can interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, tachycardia, and hypotension. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: can raise lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - Phenytoin: may reduce metronidazole plasma levels, decreasing efficacy. - Phenobarbital: can lower drug concentrations through enzyme induction. - Erythromycin: may increase metronidazole levels, requiring dose adjustment.